Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV005015903 | SCV005647572 | likely pathogenic | Age related macular degeneration 9; Atypical hemolytic-uremic syndrome with C3 anomaly; Complement component 3 deficiency | 2024-03-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV005112721 | SCV005788961 | pathogenic | not provided | 2024-03-07 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Val942Glyfs*13) in the C3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in C3 are known to be pathogenic (PMID: 12462331, 14639503, 21501302). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with C3-related conditions. For these reasons, this variant has been classified as Pathogenic. |